# US 10,869,833 B2 · Drug delivery devices for delivery of ocular therapeutic agents > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,869,833 B2 - Document ID: US10869833B2 - Status: Granted - Kind: B2 - Application number: 15/787,600 - Filed: 2017-10-18 - Published: 2018-08-16 - Granted: 2020-12-22 - Earliest claimed: 2010-05-17 - Applicants: Novaer Holdings, Inc. - Inventors: Casey Kopczynski; Cheng-Wen Lin; Chris Sutay - Web page: https://patentgrep.com/patent/US10869833B2 ## CPC - A61K 9/0051: {Ocular inserts or implants} - A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts} - A61K 31/00: Medicinal preparations containing organic active ingredients - A61K 31/215: of carboxylic acids - A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} - A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin - A61P 27/02: Ophthalmic agents - A61P 27/06: Antiglaucoma agents or miotics - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device. ## Claims ### Claim 1 A device for insert in the eye, the device comprising: a first portion comprising a rate-limiting water-permeable polymer; a second portion fused to the first portion, the second portion including a composition comprising latanoprost free acid salt as an active agent; and a third portion fused to the second portion, the third portion comprising a rate-limiting water-permeable polymer, wherein the rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device and wherein the rate-limiting water-permeable polymer is configured to release the latanoprost free acid salt at a rate of 0.00025 to 0.0075 μg/h when the drug delivery device is to be placed episclerally or at a rate of 0.0005 to 0.015 μg/h when the drug delivery device is to be placed supraconjunctivally, and wherein the device is configured to release 70% to 90% of the latanoprost free acid salt over a period of at least 30 days. ### Claim 2 (depends on 1) The device set forth in claim 1, wherein at least one of the first portion and third portion comprises a polymer selected from the group consisting of: ethylene vinyl acetate with a vinyl acetate content of about 10% to about 50% by weight (EVA-10-50) and ethylene vinyl alcohol with a vinyl alcohol content of about 40% to about 80% by weight (EVOH-40-80). ### Claim 3 (depends on 1) A method of treating an ocular condition comprising implanting the device of claim 1 into a conjunctiva of an eye. ### Claim 4 (depends on 3) The method of claim 3, wherein the device is implanted episclerally in the eye and the active agent is released at a rate of about 0.00025 to about 0.0075 micrograms/hr. ### Claim 5 (depends on 4) The method of claim 4, wherein the active agent comprises latanoprost arginine salt. ### Claim 6 (depends on 3) The method of claim 3, wherein the device is implanted supraconjunctivally in the eye and the active agent is released at a rate of 0.00025 to 0.0075 micrograms/hr. ### Claim 7 (depends on 6) The method of claim 6, wherein the active agent comprises latanoprost arginine salt. ### Claim 8 (depends on 1) The device of claim 1, wherein the device is substantially cylindrical-shaped. ### Claim 9 (depends on 1) The device of claim 1, wherein the portion and the third portion are manufactured from the same polymer. ### Claim 10 (depends on 1) The device of claim 1, wherein the first polymer portion and the third portion are manufactured from a non-water soluble polymer. ### Claim 11 (depends on 10) The device of claim 10, wherein the non-water soluble polymer is ethylene vinyl acetate having a vinyl acetate content of from 9% to 50% by weight. ### Claim 12 (depends on 11) The device of claim 11, wherein the ethylene vinyl acetate content in the first portion and the third portion are the same. ### Claim 13 (depends on 11) The device of claim 11, wherein the ethylene vinyl acetate content in the first portion and the third portion are different. ### Claim 14 (depends on 3) The method of claim 3, wherein the device is inserted into the upper fornix of the eye or the lower fornix of the eye.